A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacokinetic parameter (Cmax)
Timeframe: Over 240 hours after administration in blood
Pharmacokinetic parameter (AUCt)
Timeframe: Over 240 hours after administration in blood